Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Open-label, Multicenter Study Comparing the Efficacy and Safety of NRT6003 Injection With Conventional Transarterial Chemoembolization (cTACE) in Chinese Patients With Unresectable Hepatocellular Carcinoma (HCC)

NCT06900543 is registered in ClinicalTrials.gov with Chengdu New Radiomedicine Technology Co. LTD. as lead sponsor.

NCT NCT06900543
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06900543 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Open-label, Multicenter Study Comparing the Efficacy and Safety of NRT6003 Injection With Conventional Transarterial Chemoembolization (cTACE) in Chinese Patients With Unresectable Hepatocellular Carcinoma (HCC)
Lead sponsor
Chengdu New Radiomedicine Technology Co. LTD.
Phase
Phase 3
Overall status
Active, not recruiting
Start date
April 15, 2025
Completion date
December 31, 2027
Enrollment
108 (estimated)
Sites
19

Conditions

As the registry lists them; a condition with its own page is linked.

unresectable hepatocellular carcinoma